Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

HALOBETASOL PROPIONATE AND TAZAROTENE

HALOBETASOL PROPIONATE; TAZAROTENE

Standard Dose
0.01%;0.045%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview HALOBETASOL PROPIONATE AND TAZAROTENE is listed in Drugs@FDA under application 217190 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient HALOBETASOL PROPIONATE; TAZAROTENE Form and strength LOTION;TOPICAL - 0.01%;0.045% Sponsor SUN PHARMA CANADA Submission history Latest submission status date: 2025-05-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview HALOBETASOL PROPIONATE AND TAZAROTENE is listed in Drugs@FDA under application 217190 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient HALOBETASOL PROPIONATE; TAZAROTENE Form and strength LOTION;TOPICAL - 0.01%;0.045% Sponsor SUN PHARMA CANADA Submission history Latest submission status date: 2025-05-02 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.